Bill Gunderson

Every day I do my best to prepare for what the market will bring next. But let’s talk about the present and what is out there today because the money is made TODAY.

Predicting the future and investing on those predictions is dicey business at best. Instead, one is much better-off dealing with the facts that present themselves today. And the facts today are that the 4.6 year old bull market still remains intact. American pharmaceutical, technology, oil and gas exploration, and small and midcap stocks continue to dominate and lead the market.

Having said that, I want to discuss one of the few large cap stocks that is handily beating the market. This stock does not fit the current bill of a stock that is favored into today’s market.

Data from Best Stocks Now App

Regeneron Pharmaceuticals (REGN) is a company headquartered in Tarrytown, New York that has many drugs in its pipeline, including a new drug that slashes bad cholesterol in half! Imagine that: now I can have my cream cheese wontons and eat them too!

I have talked and written about it many times before as it is one of the best large caps in the market and it is also a Best Stock Now! In fact, REGN is a big holding of mine at Gunderson Capital Management, in the conservative growth account where I like to put large and midcap stocks.

Now one might question the risk-factor of this biotech, but what we need not forget is that at one time Johnson & Johnson (JNJ), Merck (MRK), and Abbot Labs (ABT) all were $30 billion companies. So is REGN going to grow-up to be another Merck or Johnson & Johnson? I do not know. However, what I can tell you is REGN one of the most impressive drug stocks in the market today.

In fact, REGN is looking forward to 56% growth in earnings this year as opposed to last year! So let’s go through the Gunderson-grading drill. I like to begin with performance


Data from Best Stocks Now App

Over the last 10 years REGN has averaged 36% per year to investors—put that up against Johnson & Johnson (JNJ)!

Data from Best Stocks Now App

Over the last five years Regeneron has delivered 76% per year; compare that against Merck (MRK)!

Over the last three years RGN has delivered a whopping 118% per year—put that up against Bristol-Myers (BMY)!

Bill Gunderson

Bill Gunderson is the CEO and Chief Market Strategist of Gunderson Capital Managment in San Diego, CA. He is also a professional money manager, former research analyst, author of Best Stocks Now.

Due to the overwhelming enthusiasm of our readers it has become necessary to transfer our commenting system to a more scalable system in order handle the content.

Check out Townhall's Polls on LockerDome on LockerDome